Opendata, web and dolomites
Horizon2020 projects coordinated by "PILA PHARMA AB"
| # | ||||
|---|---|---|---|---|
| 1 | XEND Clinical assessment of PILA PHARMA’s TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent | 2019 | 71˙429.00 | 50˙000.00 |
| # | ||||
|---|---|---|---|---|
| 1 | XEND Clinical assessment of PILA PHARMA’s TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent | 2019 | 71˙429.00 | 50˙000.00 |